Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biohaven

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The primary endpoint measured the change in the severity of symptoms among patients from the baseline to week 48 of treatment. It did not reach statistical significance in the overall SCA population as…

Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review

Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review

The major indexes fell to fresh 2022 lows before bouncing late in the week. Tesla CEO Elon Musk put his Twitter deal "on hold."

Investors Business Daily

Nasdaq Leads Upside As Indexes Pull Back Into The Close; This Dow Jones Stock Nears Buy Point

Nasdaq Leads Upside As Indexes Pull Back Into The Close; This Dow Jones Stock Nears Buy Point

On Tuesday, the Nasdaq broke its biggest three-day losing streak since March 2020 and led the upside among the indexes.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Stock Market Bounces As It Tries To End Steep 3-Day Decline

The stock market rallied in afternoon trading as volatile trading continued

Investors Business Daily

Stock Market Fades, Mixed At Midday; A Defensive Group Sells Off

The stock market bounced back after a three-day sell-off, rising sharply in early trading Tuesday, as a handful of big moves punctuated the session.

Investors Business Daily

Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'

Pfizer will acquire migraine drugmaker Biohaven Pharmaceuticals for nearly $12 billion in a deal that sent BHVN stock rocketing.

Investors Business Daily

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion. Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock. The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

inkl

Read news from The Economist, FT, and more,
with one subscription

Pfizer to spend $11.6B on migraine treatment maker Biohaven

Pfizer to spend $11.6B on migraine treatment maker Biohaven

Pfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own

The Independent UK

European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine

European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine

European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.

Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals

Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals

Biohaven inked a pair of deals Friday to outfit its pipeline with several new drugs, but BHVN stock plummeted on quarterly losses.

Investors Business Daily

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has

People

Christopher Raymond

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

GlobalFoundries

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play